Posted by Michael Wonder on 18 Oct 2023
Merck receives positive EU CHMP opinion for Prevymis for prevention of CMV disease in high risk adult kidney transplant recipients and extended 200 day dosing in adult HSCT recipients at risk for late CMV infection and disease
17 October 2023 - Merck today announced that the CHMP of the EMA has recommended the approval of Prevymis (letermovir) for prophylaxis of cytomegalovirus disease in adult kidney transplant recipients at high risk (donor CMV seropositive/recipient CMV seronegative).
The CHMP has also recommended the approval for extending dosing for Prevymis from 100 days to 200 days following transplant in adult CMV seropositive recipients of an allogeneic haematopoietic stem cell transplant who are at risk for late CMV infection and disease.
